On Jul. 6, 2020, Anixa Biosciences announced that it and partner OntoChem had completed the initial in silico screening process of their drug discovery program and identified an additional specific compound, as well as multiple analogs, that could function as inhibitors of the main protease (Mpro) of the virus. As previously announced, Anixa and OntoChem have identified four compounds that could disrupt the function of a viral enzyme called an endoribonuclease (also known as Non-Structural Protein-15, or NSP-15).